How to Buy Gyre Therapeutics Stock
Gyre Therapeutics Inc
Gyre Therapeutics, Inc. , a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
Gyre Therapeutics stock last closed at $7.59, down 3.92% from the previous day, and has decreased 46.02% in one year. It has overperformed other stocks in the Biotechnology industry by 0.04 percentage points. Gyre Therapeutics stock is currently +24.22% from its 52-week low of $6.11, and -60.05% from its 52-week high of $19.00.
As of Sep 16, 2025, there are 96.31M shares of GYRE outstanding. The market cap of GYRE is $731.02M. In the past 24 hours, 54,300 GYRE shares were traded.
How to Buy Gyre Therapeutics Stock
Not sure how to invest in Gyre Therapeutics stock? Here's how.
- Figure out where to buy Gyre Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Gyre Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Choose your payment method and add your info.
- Research Gyre Therapeutics stock: The Gyre Therapeutics ticker symbol is GYRE. Is Gyre Therapeutics stock a good investment? Should you buy shares of GYRE? How do GYRE's underlying business fundamentals look? Do top analysts think Gyre Therapeutics is a good buy? Why has GYRE's stock price moved recently? (Hint: Our stock research tools can help you evaluate if GYRE is a good stock to buy).
- Place your GYRE trade: Decide if you will purchase GYRE shares at the current market price or use a limit order to purchase GYRE stock at a given price.
- Get key alerts regarding your investment in GYRE: Create a watchlist to keep track of your position in Gyre Therapeutics stock.
Step 1: Figure out where to buy Gyre Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy GYRE stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world markets: From Technology to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal info so you are able to invest in GYRE today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to open a new brokerage account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have opened your account on the best app for stock investing, you can securely and quickly fund your account:
Check out the walkthrough below to see the process of depositing funds into your new investment account.
Step 4: Research Gyre Therapeutics stock
After you have figured out the best place to buy Gyre Therapeutics stock, it's absolutely critical to research their stock prior to buying, so you actually comprehend the risk as well as the upside.
Gyre Therapeutics shares at a glance
Fundamentals of GYRE
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on GYRE's stock page.
Is GYRE stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge GYRE's intrinsic value.
Using relative valuations metrics:
- GYRE may be undervalued based on its P/E ratio of 189.75x, relative to Biotechnology industry P/E ratio of -95.43x
- GYRE may be overvalued based on its P/B ratio of 7.94x, relative to Biotechnology industry P/B ratio of 4.68x
- GYRE could be overvalued based on its PEG ratio of 16.25x
You can access more valuation analysis on GYRE's stock here.
How do GYRE Financials look?
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the GYRE balance sheet.
- GYRE earnings of $7.01M is not enough to cover its interest payments.
- GYRE's operating cash flow of $927.00k allows it to safely service it's debt of $1.39M.
- GYRE profit margin has gone up from -77% to 4.1% in the past year.
- GYRE has a low debt to equity ratio of 0.25.
- There are more short-term assets than long-term liabilities on the GYRE balance sheet.
Failed Financial Due Diligence Checks:
- Total GYRE debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Gyre Therapeutics stock, according to analysts?
Out of 1 sell side analysts who give forecasts on GYRE, the consensus analyst rating on Gyre Therapeutics is a Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are saying on the Gyre Therapeutics stock forecast page.
GYRE Technical Indicators
Is GYRE Making Money?
Last year, GYRE revenue was $102.19M. In the past 5 year, GYRE's revenue has increased by 41.49% per year. This was slower than the Biotechnology industry average of 67.22%.
Find out more about GYRE's earnings and revenue performance here.
Latest Insiders Trades at GYRE
Over the past year, insiders at GYRE have bought more shares than they have sold.
Songjiang Ma, President of GYRE, was the latest GYRE insider to sell. They sold $5,619.06 worth of GYRE shares on May 28, 2025.
Get more info about who owns GYRE stock here.
Does GYRE stock generate passive income?
No, Gyre Therapeutics doesn't provide an income stream by paying out dividends.
GYRE Social Trading Data
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Place your GYRE trade
You have two primary options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a given dollar amount limit, place a limit order.
Hit the Open button and eToro will execute the order.
If you want additional help investing in stocks on eToro, watch the helpful video below:
Step 6: Get key alerts regarding your investment in GYRE
Now that you own some GYRE stock, you'll want to keep up with your investment.
Create a watchlist to keep tabs on your GYRE stock.
GYRE Feed
How to Buy Stock in Gyre Therapeutics
To reiterate, here are the 6 steps for buying Gyre Therapeutics stock:
- Figure out where to buy Gyre Therapeutics stock
- Sign up for a brokerage account
- Deposit funds into your investment account
- Research Gyre Therapeutics stock
- Place your GYRE trade
- Get key alerts regarding your investment in GYRE
If you need a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to watch your new investment in Gyre Therapeutics, hit the button below to create your watchlist.
More Stock Buying Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.